Shanghai Ke Pharmaceutical

Kechow Pharma is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the discovery and development of innovative small molecule therapeutics for oncology. The company's lead candidate, tunlametinib (HL-085), is a potent and selective MEK inhibitor that has recently received approval in China for the treatment of NRAS-mutant advanced melanoma. Kechow's pipeline focuses on targeting the MAPK/ERK signaling pathway, with several programs investigating combination therapies for various solid tumors, including lung and colorectal cancers. By leveraging its expertise in medicinal chemistry and cancer biology, Kechow Pharma aims to address significant unmet medical needs in the global oncology market.